ArrhythmiaCONNECTNCT00402246
CONNECT Study - Clinical Evaluation Of Remote NotificatioN to rEduCe Time to Clinical Decision
A study testing Remote Management and In-Office Care in people with Arrhythmia and Tachycardia, run by Medtronic Cardiac Rhythm and Heart Failure at 127 sites in United States.
Trial summary
The purpose of this study is to determine whether the ability of clinicians to receive and review information from patients implanted with a heart device over the internet (remote care) is comparable to patients who are seen in-office for routine visits to check the status of their device. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Arrhythmia, Tachycardia, Atrial Fibrillation
- What is being tested?
- Remote Management and In-Office Care
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,009 participants
- Where
- 127 sitesUnited States
- Study dates
- Nov 2006to Sep 2009
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient will be implanted with a Medtronic Conexus-enabled Cardiac Resynchronization Therapy Defibrillator (CRT-D) or Implantable Cardioverter-Defibrillator (DR-ICD) device.
Who cannot join
- Patient has permanent rapid beats in the upper chamber of the heart (Atrial Fibrillation) - (constant atrial fibrillation in which pharmacological therapy or cardioversion failed or not attempted).
- Patient plans to be on chronic warfarin therapy post-implant and is no longer receiving therapies to attempt to control the rhythm of the beats in their atrium.
- Patient has a previous ICD, CRT-D, Implantable Pulse Generator (IPG) or Cardiac Resynchronization Therapy Pacemaker (CRT-P).
Trial locations and contacts
127 sites in 1 country.
127 sites in 1 country
United States127 sites
Study site
Abington, Pennsylvania
Study site
Amarillo, Texas
Study site
Ames, Iowa
Study site
Ann Arbor, Michigan
Study site
Ashland, Kentucky
Study site
Atlanta, Georgia
Study site
Aurora, Illinois
Study site
Baltimore, Maryland
Study site
Bismarck, North Dakota
Study site
Bloomington, Indiana
Study site
Boston, Massachusetts
Study site
Bridgeport, Connecticut
Study site
Brooksville, Florida
Study site
Chattanooga, Tennessee
Study site
Chelmsford, Massachusetts
Study site
Cherry Hill, New Jersey
Study site
Chicago, Illinois
Study site
Cincinnati, Ohio
Study site
Clearwater, Florida
Study site
Cleveland, Ohio
Study site
Colorado Springs, Colorado
Study site
Columbia, Missouri
Study site
Columbia, South Carolina
Study site
Corpus Christi, Texas
Study site
Covington, Louisiana
Study site
Dallas, Texas
Study site
Dayton, Ohio
Study site
Daytona Beach, Florida
Study site
Doylestown, Pennsylvania
Study site
East Palo Alto, California
Study site
Erie, Pennsylvania
Study site
Eugene, Oregon
Study site
Evansville, Indiana
Study site
Fairfax, Virginia
Study site
Fairview Park, Ohio
Study site
Florence, South Carolina
Study site
Flushing, New York
Study site
Fort Smith, Arkansas
Study site
Fredericksburg, Virginia
Study site
Gainesville, Georgia
Study site
Gastonia, North Carolina
Study site
Germantown, Tennessee
Study site
Glen Burnie, Maryland
Study site
Grand Blanc, Michigan
Study site
Greenwood, South Carolina
Study site
Hattiesburg, Mississippi
Study site
Hollywood, Florida
Study site
Houston, Texas
Study site
Indianapolis, Indiana
Study site
Inglewood, California
Study site
Jacksonville, Florida
Study site
Kankakee, Illinois
Study site
Kansas City, Kansas
Study site
Kearney, Nebraska
Study site
Kettering, Ohio
Study site
Knoxville, Tennessee
Study site
Lakeland, Florida
Study site
Lancaster, Pennsylvania
Study site
Langhorne, Pennsylvania
Study site
Lanham, Maryland
Study site
Little Rock, Arkansas
Study site
Los Angeles, California
Study site
Louisville, Kentucky
Study site
Lynchburg, Virginia
Study site
Madison, Wisconsin
Study site
Manchester, New Hampshire
Study site
Mayfield Heights, Ohio
Study site
Mesa, Arizona
Study site
Mexico, Missouri
Study site
Milwaukee, Wisconsin
Study site
Mineola, New York
Study site
Minneapolis, Minnesota
Study site
Mobile, Alabama
Study site
Moline, Illinois
Study site
Morgantown, West Virginia
Study site
Napa, California
Study site
Nashville, Tennessee
Study site
New York, New York
Study site
Newark, New Jersey
Study site
Oklahoma City, Oklahoma
Study site
Omaha, Nebraska
Study site
Orlando, Florida
Study site
Overland Park, Kansas
Study site
Owensboro, Kentucky
Study site
Pensacola, Florida
Study site
Petoskey, Michigan
Study site
Philadelphia, Pennsylvania
Study site
Portland, Oregon
Study site
Portsmouth, Virginia
Study site
Poughkeepsie, New York
Study site
Raleigh, North Carolina
Study site
Rancho Mirage, California
Study site
Randallstown, Maryland
Study site
Ridgewood, New Jersey
Study site
Rochester, New York
Study site
Rockford, Illinois
Study site
Safety Harbor, Florida
Study site
Saginaw, Michigan
Study site
Saint Cloud, Minnesota
Study site
Saint Joseph, Michigan
Study site
Saint Paul, Minnesota
Study site
Salisbury, Maryland
Study site
San Antonio, Texas
Study site
San Bernardino, California
Study site
San Diego, California
Study site
Santa Rosa, California
Study site
Sarasota, Florida
Study site
Scottsdale, Arizona
Study site
Springfield, Illinois
Study site
Springfield, Missouri
Study site
St Louis, Missouri
Study site
St. Petersburg, Florida
Study site
Takoma Park, Maryland
Study site
Tampa, Florida
Study site
The Woodlands, Texas
Study site
Tucson, Arizona
Study site
Vero Beach, Florida
Study site
Washington D.C., District of Columbia
Study site
Wayne, New Jersey
Study site
West Orange, New Jersey
Study site
Whitehall, Ohio
Study site
Williamsville, New York
Study site
Winston-Salem, North Carolina
Study site
Wormleysburg, Pennsylvania
Study site
Wyomissing, Pennsylvania
Study site
York, Pennsylvania
Study site
Ypsilanti, Michigan
About this study
The purpose of this study is to determine whether the ability of clinicians to receive and review information from patients implanted with a heart device over the internet (remote care) is comparable to patients who are seen in-office for routine visits to check the status of their device.
- Conditions
- Arrhythmia, Tachycardia, Atrial Fibrillation, Ventricular Fibrillation
- Being tested
- Remote Management, In-Office Care
- Keywords
- Randomized Controlled Trials, Defibrillators, Remote Consultation
- Medical subject headings
- Arrhythmias, Cardiac, Tachycardia, Atrial Fibrillation, Ventricular Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Remote ManagementOther
The Remote Management method of treating patients consists of 3 components:
CareAlerts: Device alerts that are triggered by either device integrity issues or arrhythmic issues with the patient (e.g. multiple shocks delivered for a ventricular arrhythmia, more than 12 hours of atrial arrhythmias occurring in a day)
Conexus: the device feature which allows the device to wirelessly transmit information (possibly triggered by a CareAlert) to a patient monitor that is hooked up a patient's phone line
CareLink: the Medtronic system which allows device data to be transmitted from a patient's monitor through the phone line to ultimately be displayed on a secure website for viewing by the patient's physician.
The combination of these 3 components allow the patient's device to transmit information relating to either a device issue or patient issue to be viewed by a clinician without the patient having to take direct action.
In-Office CareOther
Routine in-office care
| Study group | Role | What they receive |
|---|---|---|
| Remote Arm | Experimental | Remote Management Receives: Other: Remote Management |
| In-office Arm | Active comparator | In-Office Care Receives: Other: In-Office Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time Per Patient From a Clinical Event to a Clinical Decision in Response to Arrhythmias, Cardiovascular (CV) Disease Progression, and Device Issues
Days from device detection of a clinical event to a decision being made in response to the event, as reported by the clinician or as evidenced by device data obtained at interrogation. A clinical event could be any of the following that satisfied pre-specified thresholds: arrhythmias (e.g. at least 12 hours of atrial tachycard/atrial fibrillation in a day), cardiovascular disease progression (e.g. multiple device shocks delivered to terminate a single episode), or device issues (e.g. low battery).
Measured: Enrollment to last visit (up to 15 month post-implant)
Secondary outcomes (16)
Health Care Utilization (HCU)
Count of HCU visits for each HCU type (cardiovascular (CV) hospitalizations, cardiovascular (CV) emergency department (ED), and cardiovascular (CV) unscheduled clinic office/urgent care visits)
Measured: Enrollment to last visit (up to 15 month post-implant)
Health Care Utilization: TEEs
Count of Transesophageal echocardiograms (TEEs) performed
Measured: Enrollment to last visit (up to 15 months post-implant)
Actions Taken for HCU Visits
Count of HCU visits that involved specific actions taken
Measured: Enrollment to last visit (up to 15 month post-implant)
Clinically Meaningful Alerts
Count of clinically meaningful alerts as classified by the clinician
Measured: Enrollment to last visit (up to 15 month post-implant)
Symptomatic AT/AF Alerts
AT/AF represents atrial tachycardia or atrial fibrillation which are arrhythmias involving rapid beating of the atrial chambers of the heart. The devices in this study store how many hours each day that a patient experiences AT/AF. The patient may not be aware they are experiencing these atrial arrhythmias, but if the AT/AF is accompanied by symptoms, the AT/AF is said to be symptomatic AT/AF. Devices in this study have an alert that fires if the patient experiences at least a programmed amount of AT/AF in a day. Measure is count of symptomatic AT/AF alerts as classified by the clinician
Measured: Enrollment to last visit (up to 15 month post-implant)
AT/AF Alert Treatment
Count of the treatment (i.e. hospitalization, ED visit, unscheduled clinic office/urgent care visits) in response to the AT/AF alerts
Measured: Enrollment to last visit (up to 15 month post-implant)
Time Per Patient From a Clinical Event Onset to a Clinical Decision for Symptom-driven Device Interrogations
Days from a symptom-driven device interrogation event onset to a clinical decision being made in response to the event as reported by the clinician. An event is defined as a subject complaint received by the managing clinician in which the clinician determines that he/she must interrogate the subject's device to properly treat the subject.
Measured: Enrollment to last visit (up to 15 month post-implant)
Time Per Patient From a Clinical Event Onset to a Clinical Decision for Both Device Events and Symptom-driven Device Interrogations
Days from device detection of a clinical event or a symptom-driven device interrogation event onset to a clinical decision, as reported by the clinician or as evidenced by device data obtained at interrogation. A clinical event is an event as defined in the primary objective. A symptom-driven device interrogation event is defined as a subject complaint received by the managing clinician in which the clinician determines that he/she must interrogate the subject's device to properly treat the subject.
Measured: From event onset to clinical decision
CareLink Transmission Compliance
The CareLink Transmission Compliance Rate for a particular visit (e.g. 3 month visit) is the proportion (ranging from 0 to 1) of subjects with device interrogation data remotely transmitted via the CareLink system on the date it was scheduled to be sent for that visit. The proportion is a fraction in which the denominator is the number of subjects in the Remote Arm who were not exited from the trial prior to the visit of interest, and the numberator is the number of Remote Arm subjects who successfully transmitted device data via the CareLink system on the date it was scheduled to be sent.
Measured: 3, 6, 9, 12 months visits
Variability in Left Ventricular (LV) Threshold as Measured by Left Ventricular Capture Management (LVCM)
LV Capture Threshold is the required energy(volts) necessary to cause the left ventricule to contract. It is important that a device which paces the left ventricule be set to a threshold such that current conducted through the left ventricular lead will induce contraction in the left ventricle. However, these thresholds may vary over time.
The standard deviation and range (maximum LVCM threshold - minimum LVCM threshold) of the most recent 14 days of LVCM results prior to each follow-up visit were determined for each subject and used to assess within-patient variability in LV thresholds.
Measured: 1, 3, 6, 9, 12, and 15 months visits
State-Anxiety Scale
The State-Anxiety scales for each subject were obtained at multiple time points. The State-Anxiety scale was derived by summing the 20 scores in the State section of the State-Trait Anxiety Inventory (STAI) questionnaire. The State-Anxiety scales can vary from a minimum of 20 (best possible) to a maximum of 80 (worst possible).
Measured: 1, 3, 6, 9, 12, and 15 month visit
Trait-Anxiety Scale
The Trait-Anxiety scales for each subject were obtained at multiple time points. The Trait-Anxiety scale was derived by summing the 20 scores in the Trait section of the STAI questionnaire. The Trait-Anxiety scales can vary from a minimum of 20 (best possible) to a maximum of 80 (worst possible).
Measured: 1, 3, 6, 9, 12, and 15 months visits
Clinic Personnel Satisfaction With Wireless Telemetry (Telemetry + Leadless ECG).
Following the completion of enrollment in the study, participating clinicians were asked to complete a survey assessing their overall satisfaction with the wireless telemetry feature. Clinicians' rating (1=strongly disagree, 5=strongly agree) of the overall satisfaction with the wireless telemetry feature of the device
Measured: After study enrollment has been completed; on average 15.8 months after the center had enrolled its first subject
In-office Follow-up Burden: Distance Traveled
Subjects' responses to the survey. Subjects were asked to provide the distance (in miles) from their home to the clinic/hospital.
Measured: 1 month visit
In-office Follow-up Burden: Patient Expenses
On a survey at the one month visit, the patient estimated their expenses in traveling to that visit.
Measured: 1 month
In-office Follow-up Burden: Hours Absent From Work Due to Visit
Subjects were asked at their one month visit to indicate on a survey how many hours of work they were missing to attend that visit.
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Nov 2006 (estimated)
- Study startNov 2006
- Primary completionSep 2009
- Study completionSep 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for ArrhythmiaStudies of the same condition, open and under way.
- More trials run by Medtronic Cardiac Rhythm and Heart FailureThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 2,009 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Symbios Clinical
- Investigators
- George Crossley, M.D., Principal investigator, Mid-State Cardiology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00402246
- Sponsor's protocol ID
- 605
- Acronym
- CONNECT
- Status last verified
- Feb 2011
- First submitted
- 17 Nov 2006
- Last updated
- 25 Feb 2011
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Crossley GH, Boyle A, Vitense H, Chang Y, Mead RH; CONNECT Investigators. The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial: the value of wireless remote monitoring with automatic clinician alerts. J Am Coll Cardiol. 2011 Mar 8;57(10):1181-9. doi: 10.1016/j.jacc.2010.12.012. Epub 2011 Jan 20.
PubMed 21255955Crossley G, Boyle A, Vitense H, Sherfesee L, Mead RH. Trial design of the clinical evaluation of remote notification to reduce time to clinical decision: the Clinical evaluation Of remote NotificatioN to rEduCe Time to clinical decision (CONNECT) study. Am Heart J. 2008 Nov;156(5):840-6. doi: 10.1016/j.ahj.2008.06.028. Epub 2008 Sep 11.
PubMed 19061696
Study at a glance
From the registry record, last updated by the sponsor on 25 Feb 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CONNECT Study - Clinical Evaluation Of Remote NotificatioN to rEduCe Time to Clinical Decision
- ClinicalTrials.gov ID
- NCT00402246
- Acronym / sponsor ID
- CONNECT / 605
- Conditions
- Arrhythmia, Tachycardia, Atrial Fibrillation, Ventricular Fibrillation
- Keywords
- Randomized Controlled Trials, Defibrillators, Remote Consultation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 2,009 participants (actual)
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart FailureIndustry (pharma, biotech, devices)
- Collaborators
- Symbios Clinical
- Study start
- Nov 2006
- Primary completion
- Sep 2009 (actual)
- Study completion
- Sep 2009 (actual)
- First posted
- 22 Nov 2006 (estimated)
- Results
- Posted 16 Feb 2011
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether the ability of clinicians to receive and review information from patients implanted with a heart device over the internet (remote care) is comparable to patients who are seen in-office for routine visits to check the status of their device.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Remote Arm | Experimental | Other: Remote ManagementRemote Management |
| In-office Arm | Active comparator | Other: In-Office CareIn-Office Care |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patient will be implanted with a Medtronic Conexus-enabled Cardiac Resynchronization Therapy Defibrillator (CRT-D) or Implantable Cardioverter-Defibrillator (DR-ICD) device.
Key exclusion criteria (3 listed)
- Patient has permanent rapid beats in the upper chamber of the heart (Atrial Fibrillation) - (constant atrial fibrillation in which pharmacological therapy or cardioversion failed or not attempted).
- Patient plans to be on chronic warfarin therapy post-implant and is no longer receiving therapies to attempt to control the rhythm of the beats in their atrium.
- Patient has a previous ICD, CRT-D, Implantable Pulse Generator (IPG) or Cardiac Resynchronization Therapy Pacemaker (CRT-P).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Remote ManagementThe Remote Management method of treating patients consists of 3 components: CareAlerts: Device alerts that are triggered by either device integrity issues or arrhythmic issues with the patient (e.g. multiple shocks delivered for a ventricular arrhythmia, more than 12 hours of atrial arrhythmias occurring in a day) Conexus: the device feature which allows the device to wirelessly transmit information (possibly triggered by a CareAlert) to a patient monitor that is hooked up a patient's phone line CareLink: the Medtronic system which allows device data to be transmitted from a patient's monitor through the phone line to ultimately be displayed on a secure website for viewing by the patient's physician. The combination of these 3 components allow the patient's device to transmit information relating to either a device issue or patient issue to be viewed by a clinician without the patient having to take direct action. | Other | Remote Arm |
| In-Office CareRoutine in-office care | Other | In-office Arm |
Primary outcome
Time Per Patient From a Clinical Event to a Clinical Decision in Response to Arrhythmias, Cardiovascular (CV) Disease Progression, and Device Issues
Time frame: Enrollment to last visit (up to 15 month post-implant)
Days from device detection of a clinical event to a decision being made in response to the event, as reported by the clinician or as evidenced by device data obtained at interrogation. A clinical event could be any of the following that satisfied pre-specified thresholds: arrhythmias (e.g. at least 12 hours of atrial tachycard/atrial fibrillation in a day), cardiovascular disease progression (e.g. multiple device shocks delivered to terminate a single episode), or device issues (e.g. low battery).
16 secondary outcomes
Health Care Utilization (HCU)
Time frame: Enrollment to last visit (up to 15 month post-implant)
Health Care Utilization: TEEs
Time frame: Enrollment to last visit (up to 15 months post-implant)
Actions Taken for HCU Visits
Time frame: Enrollment to last visit (up to 15 month post-implant)
Clinically Meaningful Alerts
Time frame: Enrollment to last visit (up to 15 month post-implant)
Symptomatic AT/AF Alerts
Time frame: Enrollment to last visit (up to 15 month post-implant)
AT/AF Alert Treatment
Time frame: Enrollment to last visit (up to 15 month post-implant)
Time Per Patient From a Clinical Event Onset to a Clinical Decision for Symptom-driven Device Interrogations
Time frame: Enrollment to last visit (up to 15 month post-implant)
Time Per Patient From a Clinical Event Onset to a Clinical Decision for Both Device Events and Symptom-driven Device Interrogations
Time frame: From event onset to clinical decision
CareLink Transmission Compliance
Time frame: 3, 6, 9, 12 months visits
Variability in Left Ventricular (LV) Threshold as Measured by Left Ventricular Capture Management (LVCM)
Time frame: 1, 3, 6, 9, 12, and 15 months visits
State-Anxiety Scale
Time frame: 1, 3, 6, 9, 12, and 15 month visit
Trait-Anxiety Scale
Time frame: 1, 3, 6, 9, 12, and 15 months visits
Clinic Personnel Satisfaction With Wireless Telemetry (Telemetry + Leadless ECG).
Time frame: After study enrollment has been completed; on average 15.8 months after the center had enrolled its first subject
In-office Follow-up Burden: Distance Traveled
Time frame: 1 month visit
In-office Follow-up Burden: Patient Expenses
Time frame: 1 month
In-office Follow-up Burden: Hours Absent From Work Due to Visit
Time frame: 1 month
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Feb 2011.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 21255955Crossley GH, Boyle A, Vitense H, Chang Y, Mead RH; CONNECT Investigators. The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial: the value of wireless remote monitoring with automatic clinician alerts. J Am Coll Cardiol. 2011 Mar 8;57(10):1181-9. doi: 10.1016/j.jacc.2010.12.012. Epub 2011 Jan 20.
- Derived from this study: PubMed 19061696Crossley G, Boyle A, Vitense H, Sherfesee L, Mead RH. Trial design of the clinical evaluation of remote notification to reduce time to clinical decision: the Clinical evaluation Of remote NotificatioN to rEduCe Time to clinical decision (CONNECT) study. Am Heart J. 2008 Nov;156(5):840-6. doi: 10.1016/j.ahj.2008.06.028. Epub 2008 Sep 11.
Related trials for Arrhythmia
RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Atrial Fibrillation (AF)
Enrolling by invitation
VINTAGE (Ventricular Intramyocardial Navigation for Tachycardia Ablation Guided by Electrograms) Using Commercial Off-The-Shelf (COTS) Catheters
Ventricular Arrhythmia
Recruiting
Peer-Mentor Support for Vulnerable Patients With Atrial Fibrillation
Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
Enrolling by invitation
EDEN Intracardiac Electrogram Recording and Classifying System
Ventricular Arrhythmia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
George Crossley, M.D. principal investigator
Mid-State Cardiology
127 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Remote Management and In-Office Care in people with Arrhythmia and Tachycardia, run by Medtronic Cardiac Rhythm and Heart Failure at 127 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Feb 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 127 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 16 Feb 2011). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time Per Patient From a Clinical Event to a Clinical Decision in Response to Arrhythmias, Cardiovascular (CV) Disease Progression, and Device Issues (time frame: Enrollment to last visit (up to 15 month post-implant)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00402246, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2011.